The treatment of coronary artery disease (CAD), peripheral artery disease (PAD) and ischemic heart disease (IHD), has been radically modified in the recent past by the implementation of the results of two randomized controlled studies. The PEGASUS-TIMI-54 trial, showing as 60mg ticagrelor/BID may significantly reduce the incidence of the primary composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke [1], was the first study to demonstrate a clinical benefit of prolonged dual anti-platelet therapy (DAPT), beyond the first year after an acute MI (AMI), although with a reduced dose of second additional anti-platelet drug.
